Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1

Conditions

Multiple Myeloma 809Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Recurrence 141Neoplasms, Plasma Cell 111Lymphoma 93Leukemia 91Neoplasms 81Burkitt Lymphoma 57Vomiting 51Lymphoma, Non-Hodgkin 50Immunoglobulin Light-chain Amyloidosis 50Lymphoma, Large B-Cell, Diffuse 44Nausea 38Lymphoma, Mantle-Cell 38Prostatic Neoplasms 31Lymphoma, Follicular 30Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Breast Neoplasms 25Lung Neoplasms 23Amyloidosis 21Leukemia, Biphenotypic, Acute 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Smoldering Multiple Myeloma 15

Interventions

venetoclax 6fludarabine phosphate 5Dexamethasone 4ibrutinib 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3pomalidomide 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2pirtobrutinib 1pembrolizumab 1obinutuzumab 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carmustine, poliferprosan 20 drug combination 1auricularum 1acalabrutinib 1Sirolimus 1RG7388 1Nivolumab 1Maintenance 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Chromosome 17 deletion × Dexamethasone × Clear all
NCT01745640 2026-02-05

IFM2010-02

University Hospital, Lille

Phase 2 Completed
63 enrolled
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT04124497 2025-08-08

DPd

Fondazione EMN Italy Onlus

Phase 2 Active not recruiting
45 enrolled
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT04008888 2019-07-05

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Unknown
50 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡